These results suggest that the combination of dasatinib/gemcitabine results in a synergistic decrease in the cell proliferation and survival of ALDH1A1-enriched pancreatic cancer MIA PaCa-2 cells. The gene discussed is ALDH1A1; the disease is familial pancreatic carcinoma.